Melanoma burden by melanoma stage: Assessment through a disease transition model

Last updated on 23-8-2019 by Anonymous (not verified)

Peer reviewed scientific article




BACKGROUND: The total burden of melanoma has already been studied but little is known about the distribution of this burden amongst localised, node metastatic and distant metastatic stages. METHODS: Disability-adjusted life years (DALY) assesses disease burden, being the sum of years of life with disability (YLD) and years of life lost (YLL). A melanoma disease model was developed in order to predict the evolution of patients from diagnosis until death. The model was applied to a large cohort of 8016 melanoma patients recorded by the Belgian Cancer Registry for incidence years 2009-2011….

Associated health topics:

QR code

QR code for this page URL